Recent Updates
Recently added Catalysts

Tazemetostat

Phase 2

Relapsed/Refractory Follicular Lymphoma With EZH2 | Small molecule | Oncology |HUTCHMED (China) Limited|Last Updated: Jan 22, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment42
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05467943Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaPHASE2 COMPLETED 42 — — Jul 1, 2022Nov 1, 2024Jan 22, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
TazemetostatDRUGAll patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
Unlock Study Design Details